SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Young and Older Folk Portfolio
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: chowder12/11/2025 4:24:40 PM
3 Recommendations

Recommended By
Das Kapital
Markbn
Mili21

  Read Replies (1) of 23904
 
Novo's Dividend Remains Solid, but Competitive Risks Are Increasing

?

Downgraded on December 11, 2025


Novo Nordisk's dividend continues to rest on solid financial footing. The company maintains an AA credit rating, a healthy payout ratio near 50%, and one of the strongest balance sheets in the pharma industry.

Novo also remains one of two major players with the scale needed to compete globally in obesity and diabetes care. These fundamentals have not changed since we reaffirmed the company's Very Safe Dividend Safety Score in September.

What has evolved is our assessment of Novo's longer-term competitive environment.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News